STOCK TITAN

Essa Pharma Inc - EPIX STOCK NEWS

Welcome to our dedicated news page for Essa Pharma (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Essa Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Essa Pharma's position in the market.

Rhea-AI Summary
ESSA Pharma Inc. (NASDAQ: EPIX) to present at the 2024 Bloom Burton & Co. Healthcare Investor Conference. Key executives to host meetings. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
conferences
-
Rhea-AI Summary
ESSA Pharma Inc. announces results of Annual General Meeting of Shareholders, re-elects board members and approves key resolutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
none
-
Rhea-AI Summary
ESSA Pharma Inc. reports promising Phase 1 results for masofaniten plus enzalutamide combination in prostate cancer treatment, achieving deep reductions in PSA levels. The company maintains a strong cash position to support operations beyond 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
Rhea-AI Summary
ESSA Pharma Inc. will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company's President, CEO, COO, and CFO will host and participate in one-on-one meetings. The live webcast can be accessed on ESSA's website, and it will be archived for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
conferences
-
Rhea-AI Summary
ESSA Pharma Inc. presents updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide at the 2024 ASCO Genitourinary Cancers Symposium. The combination continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC. Across all dosing cohorts, 81% of patients achieved PSA90, 69% achieved PSA90 in less than 90 days, and 63% achieved PSA <0.2ng/mL. The Phase 2 dose expansion is currently underway, and the median time to PSA progression is at 16.6 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.64%
Tags
-
Rhea-AI Summary
ESSA Pharma Inc. (EPIX) completes Phase 1 dose escalation for masofaniten/enzalutamide combination study, reports compelling safety and efficacy data at medical meetings. Phase 2 dose expansion underway. The company also reported financial results for Q4 and fiscal year ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
Rhea-AI Summary
ESSA Pharma Inc. (NASDAQ: EPIX) will present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023, focusing on developing novel therapies for prostate cancer treatment. David R. Parkinson, President, and CEO, along with other key executives, will host one-on-one meetings and a live webcast accessible through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
conferences
-
Rhea-AI Summary
ESSA Pharma Inc. (NASDAQ: EPIX) to present at Jefferies Healthcare Conference on Nov. 15, 2023, focusing on novel therapies for prostate cancer. Key executives to host and participate in one-on-one meetings. Live webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
conferences
-
Rhea-AI Summary
ESSA Pharma Inc. has entered into an Open Market Sale Agreement with Jefferies LLC, allowing the company to sell its common shares for up to $50.0 million in aggregate sales proceeds. The offering is made in the United States under a prospectus supplement to the Company's registration statement on Form S-3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
Rhea-AI Summary
ESSA Pharma presents updated Phase 1 masofaniten (EPI-7386) clinical data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.09%
Tags
Essa Pharma Inc

Nasdaq:EPIX

EPIX Rankings

EPIX Stock Data

343.29M
24.60M
2.27%
78.66%
1.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Vancouver

About EPIX

as a clinical-stage pharmaceutical company founded on cutting-edge research, essa is focused on developing novel therapeutics for cancer patients. essa embraces innovation not only in our products but also in our approach. we're firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.